Related coverage linked through entity extraction aliases.
Jun 21, 2026
New clinical data for ANKTIVA immunotherapy in lung cancer, a study on EBV-driven resistance via ADAR1 RNA editing, and research on microbiome metabolites modulating immunotherapy response were presented at major conferences and in recent publications.
Jun 12, 2026
The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.
Jun 04, 2026
The phase 3 RAMPART trial updated results show adjuvant durvalumab monotherapy did not significantly improve disease-free survival in resected renal cell carcinoma, while the durvalumab plus tremelimumab combination showed benefit in high-risk patients. Real-world treatment decisions are also shaped by patient-specific factors.
May 19, 2026
The FDA granted Fast Track designation to COYA 302 for ALS. Phase 1 data showed tolerability and biomarker effects, and the phase 2 ALSTARS trial is underway.
May 01, 2026
European biotechs are exploring new immunotherapy targets beyond PD-1/PD-L1, including BTLA, TIGIT, and SLAMF6. Lund University researchers discovered a SLAMF6-mediated immune evasion mechanism. BioNTech and GenMab are advancing next-generation ICIs and bispecific antibodies through strategic partnerships.
Apr 20, 2026
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
Apr 19, 2026
Studies on immune checkpoint inhibitor therapy found pretreatment biomarkers strongly predicted checkpoint inhibitor-associated autoimmune diabetes, while hyperglycemia during treatment was common and did not worsen disease progression.
Apr 17, 2026
Early results from stage I of the phase 3 PRESERVE-003 trial showed gotistobart improved overall survival versus docetaxel in previously treated metastatic squamous NSCLC. Objective response rate and duration of response also favored gotistobart, while progression-free survival did not differ significantly.
Apr 02, 2026
Adagene and Incyte will collaborate on a Phase 1 study combining muzastotug with INCA33890 for MSS colorectal cancer patients, beginning in 2026. The collaboration marks the second instance where Adagene's SAFEbody technology is paired with a PD-1-based bispecific. Muzastotug has shown encouraging response rates in combination with pembrolizumab in previous trials.
Mar 10, 2026
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
Mar 04, 2026
Coya Therapeutics detailed plans for a Phase 2 trial of combination immunotherapy targeting neuroinflammation in ALS, following a four-patient study showing biomarker improvements and reported slowing of disease progression.
Feb 27, 2026
A multi-institutional study found that pairing an investigational immunotherapy with hormone therapy before surgery reduced regulatory T cells in prostate tumors and improved cancer-free outcomes in high-risk patients.
Feb 26, 2026
Lynch syndrome patients gain access to prevention vaccines in clinical trials, while immunotherapy advances depend on universal tumor testing for microsatellite instability. Cancer vaccines are moving from research to clinical reality.
Feb 24, 2026
Researchers at Stony Brook University developed an oral vaccine using modified Listeria monocytogenes that generates anti-tumor immune responses in the gut and significantly improves colorectal cancer control when combined with checkpoint inhibitors.
Feb 16, 2026
Three comprehensive reports examine the monoclonal antibody landscape, covering CD47-targeted immunotherapy pipelines, competitive analysis of 180+ companies developing mAb therapeutics, and recombinant antibody market forecasts through 2033.
Feb 17, 2026
New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.
Feb 16, 2026
CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, in patients with advanced solid tumors across nine cancer indications.
Feb 16, 2026
CStone Pharmaceuticals received FDA IND clearance to initiate a Phase II trial of CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced solid tumors across nine cancer indications.
Feb 16, 2026
CStone Pharmaceuticals received FDA IND clearance to begin a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, in advanced solid tumors across nine cancer indications.
Feb 13, 2026
Engineered regulatory T cell therapies are progressing through clinical trials for autoimmune diseases and organ transplant rejection, with CAR-Treg candidates showing promising early results in rheumatoid arthritis and other conditions.
